WMT attacks cancer from both ends by directly killing tumour cells combined with provoking an immune attack. They are a newly formed research-based company that strives to discover novel cancer therapies. Their goal is it to develop small-molecule based cancer therapies that limit tumour-autonomous growth and/or stimulate the immune system to attack the tumour. On the tumour-autonomous side, They pursue a combination of epigenetic and other intracellular targets to limit cancer growth. On the immune side, WMT targets LXR, a well-known nuclear receptor, to reduce tumour- associated immunosuppressive myeloid-derived suppressor cells (MDSCs). This empowers patient T-cells to actively attack the tumor. This approach should productively combine with existing T-cell enhancing checkpoint inhibitor therapies.